MTOR and hepatocellular carcinoma: We compared the overall survival of patients who were already immunosuppressed by a mTOR inhibitor before the recurrence of HCC was diagnosed with those patients whose immunosuppression did not contain a mTOR inhibitor before detection of recurrence.